Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety

References

• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116.
   PubMed Web of Science ®Google Scholar
• Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol. 2012;2012:670957.
   PubMed Web of Science ®Google Scholar
• Li T, Wu N, Dai Y, et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis. 2011;53:944–951.
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Perez-Alvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010;24:959–968.
   PubMed Web of Science ®Google Scholar
• Nakanjako D, Ssewanyana I, Mayanja-Kizza H, et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011;11:43.
   PubMed Web of Science ®Google Scholar
• Gascon RL, Narvaez AB, Zhang R, et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr. 2002;30:146–153.
   PubMed Web of Science ®Google Scholar
• Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment. J Acquir Immune Defic Syndr. 2006;43:433–435.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013;57:1038–1047.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145–1155.
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22:1615–1624.
   PubMed Web of Science ®Google Scholar
• Maggi P, Bartolozzi D, Bonfanti P, et al. Renal complications in HIV disease: between present and future. AIDS Rev. 2012;14:37–53.
   PubMed Web of Science ®Google Scholar
• Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143–2153.
   PubMed Web of Science ®Google Scholar
• Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25:4–9.
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118:3263–3272.
   PubMed Web of Science ®Google Scholar
• Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84:12082–12086.
   PubMed Web of Science ®Google Scholar
• Pettersen FO, Torheim EA, Dahm AE, et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011;85:6557–6566.
   PubMed Web of Science ®Google Scholar
• Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308:353–361.
   PubMed Web of Science ®Google Scholar
• Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS. 2013;27(8):1199.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009;151, 229–240, W249–251.
   PubMed Web of Science ®Google Scholar
• Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of tb2 in active Crohn's disease: a prospective study report. Dig Dis Sci. 2007;52:1790–1797.
   PubMed Web of Science ®Google Scholar
• Lv QW, Zhang W, Shi Q, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2014;pii, annrheumdis-2013-204807.
   Google Scholar
• Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol. 2012;74:424–436.
   PubMed Web of Science ®Google Scholar
• Lu Y, Bao X, Sun T, Xu J, Zheng W, Shen P. Triptolide attenuate the oxidative stress induced by LPS/D-GalN in mice. J Cell Biochem. 2012;113:1022–1033.
   PubMed Web of Science ®Google Scholar
• Matta R, Wang X, Ge H, Ray W, Nelin LD, Liu Y. Triptolide induces anti-inflammatory cellular responses. Am J Transl Res. 2009;1:267–282.
   PubMed Web of Science ®Google Scholar
• Premkumar V, Dey M, Dorn R, Raskin I. MyD88-dependent and independent pathways of Toll-Like Receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem Biol. 2010;10:3.
   PubMedGoogle Scholar
• Ma J, Dey M, Yang H, et al. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry. 2007;68:1172–1178.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126–133.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Y, Zhang C, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS. 2012;26:1755–1763.
   PubMed Web of Science ®Google Scholar
• Benito JM, Lopez M, Lozano S, et al. CD4+T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+T cell activation. J Infect Dis. 2005;192:2142–2146.
   PubMed Web of Science ®Google Scholar
• Benito JM, Lopez M, Lozano S, et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:373–381.
   PubMed Web of Science ®Google Scholar
• Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217–1226.
   PubMed Web of Science ®Google Scholar
• Kolber MA. CD38+CD8+T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals. AIDS. 2008;22:1937–1941.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shen L, Yang HC, Siliciano RF. Preferential cytolysis of peripheral memory CD4+T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription. J Virol. 2008;82:9154–9163.
   PubMed Web of Science ®Google Scholar
• Emu B, Moretto WJ, Hoh R, et al. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014;9:e85613.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10:655–666.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Hunt PW, Gandhi RT, et al. CD8+T-Cell Activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr. 2013;63:101–104.
   PubMed Web of Science ®Google Scholar
• Read SW, DeGrezia M, Ciccone EJ, et al. The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One. 2010;5:e11937.
   PubMed Web of Science ®Google Scholar